ArticleJournal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing2026
First-in-human experience and one-year outcomes using a novel conformal pulsed-field ablation balloon catheter for pulmonary vein isolation in paroxysmal atrial fibrillation.
Article in Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07320976 (First-in-Human Study of a Novel Conformal Pulsed-Field Ablation Balloon Catheter for Pulmonary Vein Isolation in Paroxysmal Atrial Fibrillation), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
First-in-Human Study of a Novel Conformal Pulsed-Field Ablation Balloon Catheter for Pulmonary Vein Isolation in Paroxysmal Atrial Fibrillation
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
backgroundThermal balloon catheters have improved the efficiency of pulmonary vein isolation (PVI) in atrial fibrillation (AF). Reports assessing additional safety and effectiveness of pulsed field ablation (PFA) balloon catheters for PVI are limited. This study aims to assess the safety and effectiveness of a conformal PFA balloon catheter for PVI in paroxysmal AF.
methods35 patients with paroxysmal AF (PAF) were treated with a PFBalloon catheter (Biphasic, Bipolar, 750 V). The balloon was inflated with 10:1 saline/contrast, with volume adjusted for spherical wide-antral or pear-shaped ostial-junction PV ablation to ensure optimal tissue contact. The primary safety endpoint was absence of periprocedural primary adverse events. The primary effectiveness endpoint was acute PVI. The secondary effectiveness endpoint included durable PVI assessed by remapping at three months post-ablation and 1-year clinical outcomes.
resultsAll targeted PVs (142/142) in 35 patients were acutely isolated, with 32.3 ± 4.5 applications per patient and 7.9 ± 1.0 per vein. Procedure and left atrial dwell times were 133 ± 46 and 56 ± 25 min, respectively. No hemolysis-related acute kidney injury or severe device-related complications occurred. PVI durability was 76.0% (19/25) per patient and 93.1% (95/102) per vein. After a median follow-up of 367 (interquartile range 357-380) days, 1-year Kaplan-Meier estimate for freedom from atrial arrhythmia (AF/atrial flutter/atrial tachycardia) ≥30 s was 90.7% (95% CI, 81.2%-100%).
conclusionsThe conformal PFBalloon catheter demonstrated favorable safety, efficiency, and effectiveness for PVI in PAF patients, achieving durable lesions and a high rate of freedom from atrial arrhythmias recurrence.
trial registrationclinicaltrials.gov NCT07320976.
Indexed as
Identifiers
42859373What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.